Investment
Features
FeesSafety
Academy
More
Pluang+

Compare National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares (NGG) vs Novo Nordisk A/S (NVO) Price & Performance

National Grid Transco PLC National Grid PLC (NEW) American Depositary SharesTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares vs Novo Nordisk A/S — how do they compare? National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares trades at $79.72 (market cap $78.99B), while Novo Nordisk A/S trades at $38.78 (market cap $169.24B). The key difference: Novo Nordisk A/S is far larger — about 2.1× National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals.

NGGNVO
Market Cap
$78.99B$169.24B
Volume
740,4029,314,273
Sector
UtilitiesHealth
52-Week High
$93.93$63.98
52-Week Low
$73.54$35.29
Enterprise Value
$137.22B$187.94B
Dividend Yield
4.13%4.71%
Typical Hold Time
—116 Days

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid (NGG) trades at $78.23, up 1.44% on the day, with a market cap of approximately $48.3 billion. The stock shows stable technicals near its consensus price target of $79.25. Fundamentally, it maintains strong profitability with an 18.32% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights institutional buying and a focus on grid innovation, including AI adoption.

Outlook is cautiously positive with upside to the high target of $85.50, supported by earnings momentum and strategic investments. Risks include high debt levels and regulatory pressures. Analyst consensus leans buy (55%), but hold ratings reflect concerns over capital intensity and macroeconomic sensitivity.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.06, down 1.35% on the day, with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and 59.82% ROE, while recent quarterly earnings consistently beat expectations. Technical indicators show oversold conditions with RSI at 85.35, though the stock faces resistance at $39 levels. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews of hemophilia treatments.

NVO presents a compelling value opportunity with a 9.67 P/E ratio below industry averages and 58.98% analyst buy ratings targeting $42.33. Strong cash flow generation ($119.1B operating cash flow) supports dividend payments and strategic acquisitions. Key risks include competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays, but the company's dominant GLP-1 market position and expanding oral formulations provide growth catalysts.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NGG

No sentiment data available yet.

NVO
68% Buy32% Sell
Avg holding period · 116 Days

Top news

Latest headlines on both assets

About National Grid Transco PLC National Grid PLC (NEW) American Depositary Shares

National Grid plc is a British utility company that owns and operates electricity and gas transmission networks in Great Britain, and through its US Regulated business, operates electricity and gas transmission and distribution networks serving customers in New York and Massachusetts. Its shares trade on the NYSE as American Depositary Shares under the ticker NGG.

Read more on NGG →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →